| February 1, 2028 |
ARGX |
A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy |
Trial Milestone |
Phase 1 |
| February 3, 2028 |
RAPP |
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures |
Trial Milestone |
Phase 2 |
| February 4, 2028 |
MLTX |
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis |
Trial Milestone |
Phase 3 |
| February 7, 2028 |
REGN |
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma |
Trial Milestone |
Phase 3 |
| February 8, 2028 |
NVS |
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission |
Trial Milestone |
Phase 4 |
| February 8, 2028 |
KLRA |
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide |
Trial Milestone |
Phase 1 |
| February 10, 2028 |
BIIB |
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation |
Trial Milestone |
Phase 2 |
| February 14, 2028 |
GSK |
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| February 15, 2028 |
ABBV |
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia |
Trial Milestone |
Phase 2 |
| February 15, 2028 |
ABBV |
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants |
Trial Milestone |
Phase 1 |
| February 15, 2028 |
ABBV |
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion |
Trial Milestone |
Phase 1/Phase 2 |
| February 15, 2028 |
ABBV |
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Trial Milestone |
Phase 2 |
| February 15, 2028 |
BNTX |
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV |
Trial Milestone |
Phase 1 |
| February 15, 2028 |
IONS |
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) |
Trial Milestone |
Phase 3 |
| February 15, 2028 |
NBIX |
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania |
Trial Milestone |
Phase 2 |
| February 15, 2028 |
IBRX |
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG |
Trial Milestone |
Phase 1/Phase 2 |
| February 15, 2028 |
KLRA |
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes |
Trial Milestone |
Phase 3 |
| February 15, 2028 |
ACAD |
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis |
Trial Milestone |
Phase 2 |
| February 15, 2028 |
ASND |
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders |
Trial Milestone |
Phase 3 |
| February 15, 2028 |
LBRX |
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. |
Trial Milestone |
Phase 2 |
| February 15, 2028 |
BLTE |
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease |
Trial Milestone |
Phase 2/Phase 3 |
| February 15, 2028 |
BEAM |
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease |
Trial Milestone |
Phase 1/Phase 2 |
| February 15, 2028 |
TYRA |
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer |
Trial Milestone |
Phase 2 |
| February 15, 2028 |
CLRB |
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer |
Trial Milestone |
Phase 1 |
| February 15, 2028 |
AKBA |
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G |
Trial Milestone |
Phase 2 |
| February 15, 2028 |
AGEN |
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma |
Trial Milestone |
Phase 2 |
| February 15, 2028 |
ALLO |
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease |
Trial Milestone |
Phase 1 |
| February 18, 2028 |
NVO |
A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity |
Trial Milestone |
Phase 1 |
| February 22, 2028 |
NVO |
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight |
Trial Milestone |
Phase 3 |
| February 23, 2028 |
NVO |
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight |
Trial Milestone |
Phase 3 |
| February 25, 2028 |
NVS |
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis |
Trial Milestone |
Phase 3 |
| February 25, 2028 |
NVS |
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A. |
Trial Milestone |
Phase 1 |
| February 27, 2028 |
REGN |
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) |
Trial Milestone |
Phase 2 |
| February 28, 2028 |
TAK |
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions |
Trial Milestone |
Phase 2/Phase 3 |
| February 28, 2028 |
TAK |
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis |
Trial Milestone |
Phase 2 |
| February 28, 2028 |
INCY |
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib |
Trial Milestone |
Phase 3 |
| February 28, 2028 |
ONC |
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC |
Trial Milestone |
Phase 2 |
| February 28, 2028 |
MESO |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease |
Trial Milestone |
Phase 3 |
| February 29, 2028 |
GSK |
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) |
Trial Milestone |
Phase 3 |
| February 29, 2028 |
NVO |
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis |
Trial Milestone |
Phase 2 |
| February 29, 2028 |
INCY |
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms |
Trial Milestone |
Phase 1 |
| February 29, 2028 |
EXEL |
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma |
Trial Milestone |
Phase 2 |
| February 29, 2028 |
INBS |
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors |
Trial Milestone |
Phase 1/Phase 2 |